VADs Set To Enter Big Leagues With St. Jude's Plan To Acquire Thoratec
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical says it will pay $3.4 billion to own ventricular-assist device leader Thoratec, pointing to significant synergies in the heart failure and interventional cardiology markets. The deal would thrust VADs into a diversified cardiology firm for the first time, and it includes a "go-shop" period that leaves an opening for other big device firms to enter competing bids.
You may also be interested in...
Medtronic Ups Its Heart-Failure Competitive Strength With HeartWare Buy
The deal gives Medtronic its first ventricular-assist devices and gives struggling HeartWare a needed boost.
Third Cardiovascular Giant Coming With $25 Bil. Abbott-St. Jude Deal
The previously rumored acquisition was announced on April 28, with the firms touting their extensive synergies in the cardiovascular space.
Next-Gen HeartMate Launches In St. Jude's Portfolio
Fresh-off bringing Thoratec Corp. into the fold, St. Jude Medical Inc. says its new left-ventricular-assist device unit has met a major regulatory milestone on schedule.